<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Johnson &amp; Johnson</strong>.</p>
<p>Looking at options history for Johnson &amp; Johnson (NYSE:JNJ) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 72% of the investors opened trades with bullish expectations and 0% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $411,540 and 7, calls, for a total amount of $424,038.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $135.0 to $215.0 for Johnson &amp; Johnson during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Johnson &amp; Johnson's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Johnson &amp; Johnson's whale trades within a strike price range from $135.0 to $215.0 in the last 30 days. </p>
<h3>Johnson &amp; Johnson 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766599293_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Options Call Chart" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766599293_0.png"/></p>

<h3>Significant Options Trades Detected:</h3>
<p></p><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.55</td>
<td>$210.00</td>
<td>$222.0K</td>
<td>4.1K</td>
<td align="right">569</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$29.85</td>
<td>$28.5</td>
<td>$29.44</td>
<td>$180.00</td>
<td>$147.2K</td>
<td>2.3K</td>
<td align="right">50</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$18.5</td>
<td>$17.3</td>
<td>$17.3</td>
<td>$210.00</td>
<td>$103.8K</td>
<td>119</td>
<td align="right">60</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$75.65</td>
<td>$72.7</td>
<td>$74.18</td>
<td>$135.00</td>
<td>$74.1K</td>
<td>363</td>
<td align="right">0</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/02/26</td>
<td>$1.13</td>
<td>$1.04</td>
<td>$1.05</td>
<td>$210.00</td>
<td>$60.5K</td>
<td>469</td>
<td align="right">589</td>
</tr>
</tbody>
</table><p></p>
<h3>About Johnson &amp; Johnson</h3>
<p>Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.</p>
<p>Following our analysis of the options activities associated with Johnson &amp; Johnson, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Currently trading with a volume of 1,499,052, the JNJ's price is down by -0.07%, now at $205.64. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 28 days.</li>
</ul>
<h3>What The Experts Say On Johnson &amp; Johnson</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $223.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* An analyst from RBC Capital persists with their Outperform rating on Johnson &amp; Johnson, maintaining a target price of $230. 
* An analyst from B of A Securities has decided to maintain their Neutral rating on Johnson &amp; Johnson, which currently sits at a price target of $220. 
* An analyst from Morgan Stanley persists with their Equal-Weight rating on Johnson &amp; Johnson, maintaining a target price of $197. 
* An analyst from Goldman Sachs has decided to maintain their Buy rating on Johnson &amp; Johnson, which currently sits at a price target of $240. 
* Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Johnson &amp; Johnson with a target price of $232. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Johnson &amp; Johnson with Benzinga Pro for real-time alerts.</p>

<p>Whales are bullish on Johnson & Johnson, with 72% of options trades showing positive sentiment. Analysts set an average price target of $223.8, with ratings ranging from Neutral to Buy. Significant options trades include calls and puts within a $135-$215 strike price range. Johnson & Johnson's stock is currently neutral, trading at $205.64, with anticipated earnings in 28 days. Analysts from RBC, B of A, Morgan Stanley, Goldman Sachs, and Citigroup provide varied ratings and price targets.</p>

Johnson & Johnson's Options: A Look at What the Big Money is Thinking